Shayla Smith1, Kerusha Govender2,3, Pravi Moodley2,3, Philip La Russa1, Louise Kuhn1, Moherndran Archary2. 1. From the Department of Epidemiology, Columbia University Medical Center, New York, New York. 2. Paediatric Infectious Disease Unit, University of KwaZulu-Natal, Durban, South Africa. 3. Department of Virology, National Health and Laboratory Services, Durban, South Africa.
Abstract
BACKGROUND: South African early infant diagnosis guidelines shifted to recommending an initial HIV nucleic acid-based test (NAT) test at birth in 2015. Prior to this, initial NAT was recommended at 6 weeks of age. Here we examine parameters of early infant diagnosis performance in KwaZulu-Natal before and after this change. METHODS: Data on all HIV diagnostic NAT conducted for the province between January 2013 and April 2016 were assembled and analyzed. Laboratory barcodes allowed identification of repeat tests on the same child. We evaluated coverage, positivity rates, age at testing and frequency of repeat tests across birth cohorts. RESULTS: In birth cohorts 2013 and 2014, 62.1% and 61.8%, respectively, of tests <16 weeks were done in children who were 6-8 weeks of age. In birth cohort 2015, 41.3% of tests <16 weeks were done earlier at <2 weeks of age. The percentage of children with a positive result who had at least 1 follow-up test increased from 11.5% and 13.1% in birth cohorts 2013 and 2014, respectively, to 24.8% in 2015. The percentage of infants with an initial nonpositive result who received at least 1 follow-up test did not appreciably change from 15.0% and 14.4% in 2013 and 2014, respectively, to 14.7% in 2015. CONCLUSIONS: Birth testing allows for earlier identification of HIV-infected infants who need urgent antiretroviral treatment initiation. Although follow-up testing rates may be underestimated in this data source, repeat testing rates remained low. More effort is needed to ensure infants tested at birth continue to be engaged in care and undergo follow-up testing.
BACKGROUND: South African early infant diagnosis guidelines shifted to recommending an initial HIV nucleic acid-based test (NAT) test at birth in 2015. Prior to this, initial NAT was recommended at 6 weeks of age. Here we examine parameters of early infant diagnosis performance in KwaZulu-Natal before and after this change. METHODS: Data on all HIV diagnostic NAT conducted for the province between January 2013 and April 2016 were assembled and analyzed. Laboratory barcodes allowed identification of repeat tests on the same child. We evaluated coverage, positivity rates, age at testing and frequency of repeat tests across birth cohorts. RESULTS: In birth cohorts 2013 and 2014, 62.1% and 61.8%, respectively, of tests <16 weeks were done in children who were 6-8 weeks of age. In birth cohort 2015, 41.3% of tests <16 weeks were done earlier at <2 weeks of age. The percentage of children with a positive result who had at least 1 follow-up test increased from 11.5% and 13.1% in birth cohorts 2013 and 2014, respectively, to 24.8% in 2015. The percentage of infants with an initial nonpositive result who received at least 1 follow-up test did not appreciably change from 15.0% and 14.4% in 2013 and 2014, respectively, to 14.7% in 2015. CONCLUSIONS: Birth testing allows for earlier identification of HIV-infectedinfants who need urgent antiretroviral treatment initiation. Although follow-up testing rates may be underestimated in this data source, repeat testing rates remained low. More effort is needed to ensure infants tested at birth continue to be engaged in care and undergo follow-up testing.
Authors: Kate Clouse; Audrey Pettifor; Kate Shearer; Mhairi Maskew; Jean Bassett; Bruce Larson; Annelies Van Rie; Ian Sanne; Matthew P Fox Journal: Trop Med Int Health Date: 2013-02-03 Impact factor: 2.622
Authors: Ahmad Haeri Mazanderani; Karl-Günter Technau; Nei-Yuan Hsiao; Jean Maritz; Sergio Carmona; Gayle G Sherman Journal: South Afr J HIV Med Date: 2016-05-13 Impact factor: 2.744
Authors: Anele Dube-Pule; Brian C Zanoni; Cathy Connolly; Majahonkhe Shabangu; Moherndran Archary Journal: South Afr J HIV Med Date: 2021-11-24 Impact factor: 2.744
Authors: Jane R Millar; Nomonde Bengu; Vinicius A Vieira; Emily Adland; Julia Roider; Maximilian Muenchhoff; Rowena Fillis; Kenneth Sprenger; Vuyokazi Ntlantsana; Isabella Fatti; Moherndran Archary; Andreas Groll; Nasreen Ismail; Maria C García-Guerrero; Philippa C Matthews; Thumbi Ndung'u; Maria C Puertas; Javier Martinez-Picado; Philip Goulder Journal: J Infect Dis Date: 2021-12-01 Impact factor: 5.226